Ocular Pain - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ocular Pain - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Ocular Pain - Pipeline Review, H1 2015’, provides an overview of the Ocular Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ocular Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ocular Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ocular Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ocular Pain Overview 7
Therapeutics Development 8
Pipeline Products for Ocular Pain - Overview 8
Pipeline Products for Ocular Pain - Comparative Analysis 9
Ocular Pain - Therapeutics under Development by Companies 10
Ocular Pain - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Ocular Pain - Products under Development by Companies 14
Ocular Pain - Companies Involved in Therapeutics Development 15
Auven Therapeutics Management L.L.L.P 15
Bayer AG 16
InSite Vision Incorporated 17
Kala Pharmaceuticals, Inc. 18
NicOx S.A. 19
Reata Pharmaceuticals, Inc. 20
Sylentis S.A. 21
Valeant Pharmaceuticals International, Inc. 22
Ocular Pain - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by 28
Assessment by Molecule Type 30
Drug Profiles 32
fluticasone propionate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISV-303 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ketorolac tromethamine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
loteprednol etabonate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
loteprednol etabonate next generation - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
mapracorat - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NT-71 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NT-72 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RTA-408 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RX-10045 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SYL-1001 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Ocular Pain - Recent Pipeline Updates 48
Ocular Pain - Dormant Projects 55
Ocular Pain - Product Development Milestones 56
Featured News & Press Releases 56
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 56
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 56
Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 57
Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 57
Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 58
Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 58
Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 59
Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 60
Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 61
Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables

Number of Products under Development for Ocular Pain, H1 2015 8
Number of Products under Development for Ocular Pain - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Ocular Pain - Pipeline by Auven Therapeutics Management L.L.L.P, H1 2015 15
Ocular Pain - Pipeline by Bayer AG, H1 2015 16
Ocular Pain - Pipeline by InSite Vision Incorporated, H1 2015 17
Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H1 2015 18
Ocular Pain - Pipeline by NicOx S.A., H1 2015 19
Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 20
Ocular Pain - Pipeline by Sylentis S.A., H1 2015 21
Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Ocular Pain Therapeutics - Recent Pipeline Updates, H1 2015 48
Ocular Pain - Dormant Projects, H1 2015 55